Next Article in Journal
The Liver as a Target Organ for Gene Therapy: State of the Art, Challenges, and Future Perspectives
Previous Article in Journal
Integration of Ligand-Based Drug Screening with Structure-Based Drug Screening by Combining Maximum Volume Overlapping Score with Ligand Docking
Previous Article in Special Issue
Cyclooxygenase (COX) Inhibitors and the Newborn Kidney
Article Menu

Export Article

Open AccessReview
Pharmaceuticals 2012, 5(12), 1346-1371;

Mechanistic and Pharmacological Issues of Aspirin as an Anticancer Agent

Department of Neuroscience and Imaging, Center of Excellence on Aging (CeSI), “G. d’Annunzio” University, Via dei Vestini 31, 66100 Chieti, Italy
University of Zaragoza School of Medicine, University Hospital Lozano Blesa, IIS Aragón. CIBERehd, 50009 Zaragoza, Spain
Institute for Translational Medicine and Therapeutics, University of Pennsylvania, Philadelphia, PA 19104, USA
Author to whom correspondence should be addressed.
Received: 6 November 2012 / Revised: 16 November 2012 / Accepted: 30 November 2012 / Published: 5 December 2012
(This article belongs to the Special Issue Cyclooxygenase(COX) Inhibitors)
Full-Text   |   PDF [446 KB, uploaded 6 December 2012]   |  


Recent findings have shown that aspirin, taken for several years, reduces the long-term risk of some cancers, particularly colorectal cancer. The result that aspirin benefit is detectable at daily low-doses (at least 75mg), the same used for the prevention of cardiovascular disease, positions the antiplatelet action of aspirin at the center of its antitumor efficacy. At low-doses given every 24 h, aspirin is acting by a complete and persistent inhibition of cyclooxygenase (COX)-1 in platelets (in the pre-systemic circulation) while causing a limited and rapidly reversible inhibitory effect on COX-2 and/or COX-1 expressed in nucleated cells. Aspirin has a short half-life in human circulation (approximately 20 min); nucleated cells have the ability to resynthesize the acetylated COX-isozymes within a few hours, while platelets do not. COX-independent mechanisms of aspirin, such as the inhibition of Wnt/ b-catenin and NF-kB signaling and the acetylation of extra-COX proteins, have been suggested to play a role in its chemo-preventive effects, but their relevance remains to be demonstrated in vivo at clinical doses. In conclusion, the results of clinical pharmacology and the analysis of randomized and epidemiological studies suggest that colorectal cancer and atherothrombosis share a common mechanism of disease, i.e. enhanced platelet activation in response to injury at distinct sites. View Full-Text
Keywords: aspirin; colorectal cancer; platelet; cycloooxygenase-1 aspirin; colorectal cancer; platelet; cycloooxygenase-1

Figure 1

This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Share & Cite This Article

MDPI and ACS Style

Dovizio, M.; Tacconelli, S.; Sostres, C.; Ricciotti, E.; Patrignani, P. Mechanistic and Pharmacological Issues of Aspirin as an Anticancer Agent. Pharmaceuticals 2012, 5, 1346-1371.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top